Pivotal, Randomized, Open-Label Study of Optune® (Tumor Treating Fields, 200kHz) Concomitant With Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
For more information about the trial above please contact the study team:
Principal Investigator, Scott Lindhorst, at email@example.com.
Study Coordinator, Kristina Godwin, at firstname.lastname@example.org.
Trial opened at the following institutions: Medical University of South Carolina